Breaking Finance News

Zacks Investment Research upgraded Accelerate Diagnostics Inc (NASDAQ:AXDX) to Hold in a statement released earlier today.

Having a price of $27.40, Accelerate Diagnostics Inc (NASDAQ:AXDX) traded 1.67% higher on the day. With the last close up 51.77% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. AXDX has recorded a 50-day average of $25.19 and a two hundred day average of $18.05. Trade Volume was down over the average, with 121,870 shares of AXDX changing hands under the typical 330,958

Zacks Investment Research has upgraded Accelerate Diagnostics Inc (NASDAQ:AXDX) to Hold in a statement released on 10/10/2016.

Recent Performance Chart

Accelerate Diagnostics Inc (NASDAQ:AXDX)

Accelerate Diagnostics Inc has with a 52 week low of $10.29 and a 52 week high of $28.50 and has a market cap of $0.

In addition to Zacks Investment Research reporting its target price, a total of 2 firms have reported on the stock. The consensus target price is $25.50 with 2 firms rating the stock a strong buy, 1 firm rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Accelerate Diagnostics Inc (NASDAQ:AXDX)

Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company's technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types. The Company is focused on the development of a rapid diagnostic platform, the Accelerate ID/AST System (ID/AST System or Accelerate ID/AST System), intended for the diagnosis of infectious pathogens. The ID/AST System utilizes genotypic technology to identify (ID) infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. The ID/AST System features walk-away automation and consists of a fixed instrument and single-use test kit.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.